{"id":"rituximab-window","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Infusion reactions"},{"rate":"20-40","effect":"Infections"},{"rate":"5-15","effect":"Cytopenias (neutropenia, thrombocytopenia)"},{"rate":"10-20","effect":"Fatigue"},{"rate":"5-10","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Rituximab targets CD20, a surface antigen expressed on B lymphocytes, leading to B cell depletion through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). This mechanism reduces the production of autoantibodies and pro-inflammatory cytokines. The 'window' designation likely refers to a specific treatment window or timing protocol in the phase 3 trial design.","oneSentence":"Rituximab is a chimeric monoclonal antibody that depletes B cells by binding to CD20 antigen, reducing autoimmune and inflammatory responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:32:23.242Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis (phase 3 trial context)"}]},"trialDetails":[{"nctId":"NCT02405676","phase":"PHASE2, PHASE3","title":"BNHL-2015 for Children or Adolescents in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2015-01-01","conditions":"Mature B-cell Non-Hodgkin Lymphoma","enrollment":200},{"nctId":"NCT03684980","phase":"EARLY_PHASE1","title":"LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-11-14","conditions":"Central Nervous System Lymphoma","enrollment":58},{"nctId":"NCT07410039","phase":"PHASE4","title":"Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2026-02-01","conditions":"Neuromyelitis Optica Spectrum Disorder Attack","enrollment":200},{"nctId":"NCT02339922","phase":"PHASE2","title":"Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2016-05-19","conditions":"Chronic Lymphocytic Leukemia, Follicular Lymphoma, Lymphoplasmacytic Lymphoma","enrollment":33},{"nctId":"NCT03789240","phase":"PHASE2","title":"Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-22","conditions":"Follicular Lymphoma, Non-Hodgkin's Lymphoma, NHL","enrollment":33},{"nctId":"NCT03286556","phase":"PHASE2","title":"Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2018-09-04","conditions":"Idiopathic Pulmonary Fibrosis, Acute Fatal Form","enrollment":82},{"nctId":"NCT04002947","phase":"PHASE2","title":"Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-05","conditions":"Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma, DLBCL","enrollment":132},{"nctId":"NCT03710772","phase":"PHASE2","title":"Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-05-01","conditions":"Mantle Cell Lymphoma","enrollment":51},{"nctId":"NCT01516580","phase":"PHASE3","title":"Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2011-12","conditions":"B-cell Non Hodgkin Lymphoma, Mature B-cell Leukemia Burkitt-type","enrollment":482},{"nctId":"NCT01599559","phase":"NA","title":"Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2012-10","conditions":"Primary Mediastinal B-cell Lymphoma","enrollment":540},{"nctId":"NCT01757626","phase":"PHASE1, PHASE2","title":"Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-12","conditions":"Neuroblastoma","enrollment":186},{"nctId":"NCT03964090","phase":"PHASE2","title":"Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-27","conditions":"Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma","enrollment":48},{"nctId":"NCT04745728","phase":"PHASE3","title":"Different Immunosuppressive Treatment in iMN","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2021-04-14","conditions":"Idiopathic Membranous Nephropathy","enrollment":200},{"nctId":"NCT04743739","phase":"PHASE3","title":"Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of iMN","status":"TERMINATED","sponsor":"Peking Union Medical College Hospital","startDate":"2021-04-14","conditions":"Idiopathic Membranous Nephropathy","enrollment":12},{"nctId":"NCT06682169","phase":"PHASE3","title":"Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-11-20","conditions":"Graft-versus-host Disease","enrollment":182},{"nctId":"NCT04010968","phase":"PHASE2","title":"Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"2019-09-27","conditions":"Intermediate Risk Chronic Lymphocytic Leukemia, Fit Patients, Risk-Adapted and MRD-Driven Strategy","enrollment":120},{"nctId":"NCT06765317","phase":"PHASE2","title":"A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-01-16","conditions":"Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma","enrollment":42},{"nctId":"NCT05136976","phase":"PHASE3","title":"Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2023-06-29","conditions":"Anti-MAG Neuropathy","enrollment":90},{"nctId":"NCT02427620","phase":"PHASE2","title":"Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-06-03","conditions":"Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma","enrollment":131},{"nctId":"NCT03069703","phase":"PHASE2","title":"Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-02-05","conditions":"Invasive Pneumococcal Infection","enrollment":96},{"nctId":"NCT07225439","phase":"PHASE1","title":"Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)","status":"NOT_YET_RECRUITING","sponsor":"Paolo Caimi, MD","startDate":"2025-12","conditions":"Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma","enrollment":15},{"nctId":"NCT07189325","phase":"PHASE3","title":"A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2025-09","conditions":"Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy","enrollment":250},{"nctId":"NCT07168980","phase":"PHASE2, PHASE3","title":"Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2025-07-01","conditions":"Mature B-cell Non-Hodgkin Lymphoma","enrollment":87},{"nctId":"NCT00278408","phase":"PHASE3","title":"Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"German High-Grade Non-Hodgkin's Lymphoma Study Group","startDate":"2006-01-02","conditions":"Lymphoma","enrollment":700},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT03804359","phase":"PHASE2","title":"Personalized Medicine for Membranous Nephropathy","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2020-01-14","conditions":"Idiopathic Membranous Nephropathy","enrollment":68},{"nctId":"NCT00878254","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"University of Miami","startDate":"2009-03-25","conditions":"Mantle-Cell Lymphoma","enrollment":25},{"nctId":"NCT07034508","phase":"PHASE2","title":"A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-06-20","conditions":"DLBCL - Diffuse Large B Cell Lymphoma","enrollment":134},{"nctId":"NCT07019545","phase":"PHASE2","title":"A PHASE II TRIAL AIMING TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA PREVIOUSLY TREATED WITH A THROMBOPOIETIN RECEPTOR AGONIST AND/OR RITUXIMAB AFTER CORTICOSTEROID FIRST-LINE THERAPY","status":"NOT_YET_RECRUITING","sponsor":"Hellenic Society of Hematology","startDate":"2025-06-20","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":14},{"nctId":"NCT06003283","phase":"PHASE4","title":"Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2024-01-09","conditions":"Rheumatoid Arthritis","enrollment":134},{"nctId":"NCT04436107","phase":"PHASE1","title":"Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2020-09-11","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","enrollment":66},{"nctId":"NCT00550342","phase":"PHASE2","title":"Rituximab Treatment of Focal Segmental Glomerulosclerosis","status":"WITHDRAWN","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2008-01","conditions":"Focal Segmental Glomerulosclerosis (FSGS)","enrollment":""},{"nctId":"NCT06952413","phase":"PHASE2","title":"Study of the Efficacy and Safety for Rituximab in Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)","status":"RECRUITING","sponsor":"National Center of Neurology and Psychiatry, Japan","startDate":"2025-04-09","conditions":"Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)","enrollment":30},{"nctId":"NCT03719131","phase":"PHASE2","title":"Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2019-06-05","conditions":"Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV, Stage III Melanoma","enrollment":15},{"nctId":"NCT03615105","phase":"PHASE2","title":"Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors","status":"TERMINATED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-07-25","conditions":"Acute Lymphoid Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML)","enrollment":9},{"nctId":"NCT03206671","phase":"PHASE3","title":"Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital Muenster","startDate":"2017-08-03","conditions":"Mature B-cell Non-Hodgkin Lymphoma","enrollment":650},{"nctId":"NCT03366272","phase":"PHASE2, PHASE3","title":"Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients","status":"COMPLETED","sponsor":"Universität des Saarlandes","startDate":"2017-12-05","conditions":"Lymphoma, Non-Hodgkin","enrollment":348},{"nctId":"NCT05586737","phase":"PHASE2","title":"Immunomodulatory Therapy in Women With Autoimmune Premature Ovarian Insufficiency","status":"COMPLETED","sponsor":"Angelica Lindén Hirschberg","startDate":"2019-04-29","conditions":"Autoimmune Diseases, Premature Ovarian Insufficiency","enrollment":15},{"nctId":"NCT03129828","phase":"PHASE1, PHASE2","title":"Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2","status":"COMPLETED","sponsor":"Prof. Dr. Clemens Schmitt","startDate":"2017-03-17","conditions":"Diffuse Large B Cell Lymphoma","enrollment":38},{"nctId":"NCT05221645","phase":"PHASE2","title":"Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southampton","startDate":"2022-06-27","conditions":"Diffuse Large B Cell Lymphoma","enrollment":65},{"nctId":"NCT05036577","phase":"PHASE1","title":"A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Huashan Hospital","startDate":"2021-10-10","conditions":"Primary Central Nervous System Lymphoma","enrollment":15},{"nctId":"NCT05682196","phase":"PHASE2","title":"Rituximab in Patients With Acute Rheumatic Fever","status":"SUSPENDED","sponsor":"African Academy of Methodology and Statistics","startDate":"2023-01-05","conditions":"Rheumatic Heart Disease in Children","enrollment":234},{"nctId":"NCT04083014","phase":"PHASE2","title":"Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2019-08-20","conditions":"Autoimmune Hemolytic Anemia, Autoimmune Hemolytic Anemia and Autoimmune Thrombocytopenia","enrollment":33},{"nctId":"NCT05843968","phase":"PHASE2","title":"Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Nephrotic Syndrome","status":"RECRUITING","sponsor":"Children's Hospital of Chongqing Medical University","startDate":"2023-01-29","conditions":"Nephrotic Syndrome in Children","enrollment":46},{"nctId":"NCT06325943","phase":"PHASE3","title":"Rituximab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy","status":"COMPLETED","sponsor":"Istituto Clinico Humanitas","startDate":"2019-04-01","conditions":"Polyradiculoneuropathy, Chronic Inflammatory Demyelinating","enrollment":37},{"nctId":"NCT00574730","phase":"NA","title":"CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2001-05-23","conditions":"Non-Hodgkins Lymphoma","enrollment":27},{"nctId":"NCT05734794","phase":"PHASE3","title":"Study of Rituximab Monotherapy on Children With New-onset Nephrotic Syndrome: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2023-02-09","conditions":"Nephrotic Syndrome in Children, Rituximab","enrollment":80},{"nctId":"NCT04680962","phase":"PHASE3","title":"MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis","status":"WITHDRAWN","sponsor":"Mabion SA","startDate":"2023-08-03","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT05969522","phase":"PHASE4","title":"Stratified Therapy on Pediatric AAGN","status":"UNKNOWN","sponsor":"Wang Mo","startDate":"2023-01-01","conditions":"Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, ANCA-Associated Glomerulonephritis","enrollment":200},{"nctId":"NCT00335140","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma","status":"TERMINATED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2007-08-23","conditions":"Lymphoma","enrollment":26},{"nctId":"NCT00060346","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia","status":"TERMINATED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2004-10-05","conditions":"Lymphoma","enrollment":16},{"nctId":"NCT00129090","phase":"PHASE3","title":"Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"German High-Grade Non-Hodgkin's Lymphoma Study Group","startDate":"2003-03","conditions":"Non-Hodgkin's Lymphoma (NHL)","enrollment":450},{"nctId":"NCT05834855","phase":"PHASE3","title":"Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS","status":"RECRUITING","sponsor":"Amsterdam UMC, location VUmc","startDate":"2023-04","conditions":"Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Demyelinating Autoimmune Diseases, CNS","enrollment":200},{"nctId":"NCT00096460","phase":"PHASE2, PHASE3","title":"Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2004-08","conditions":"Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma","enrollment":30},{"nctId":"NCT00114738","phase":"PHASE2","title":"EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2005-06-15","conditions":"Lymphoma, Mantle Cell, Mantle Cell Lymphoma","enrollment":53},{"nctId":"NCT05532111","phase":"NA","title":"Efficacy and Safety of the Treatment of Primary Membranous Nephropathy: A Randomized Clinical Trial","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2022-09-01","conditions":"Efficacy and Safety","enrollment":60},{"nctId":"NCT00193479","phase":"PHASE2","title":"Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2003-04","conditions":"Non-Hodgkins Lymphoma","enrollment":51},{"nctId":"NCT02149121","phase":"PHASE3","title":"PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Celltrion","startDate":"2014-08","conditions":"Rheumatoid Arthritis","enrollment":384},{"nctId":"NCT03412188","phase":"NA","title":"The Effect of Eltrombopag on the Expression of Platelet Collagen Receptor GPVI in Pediatric ITP.","status":"COMPLETED","sponsor":"Nayera Hazaa Elsherif","startDate":"2018-08-01","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":36},{"nctId":"NCT00772486","phase":"PHASE1","title":"A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL","status":"COMPLETED","sponsor":"Memgen, LLC","startDate":"2008-09","conditions":"Chronic Lymphocytic Leukemia","enrollment":13},{"nctId":"NCT00324467","phase":"PHASE2","title":"Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment","status":"UNKNOWN","sponsor":"British Columbia Cancer Agency","startDate":"2006-08","conditions":"Lymphoma, Non-Hodgkin, Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma","enrollment":150},{"nctId":"NCT02980042","phase":"PHASE3","title":"Safety of Switching From Rituximab to Ocrelizumab in MS Patients","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2017-01-01","conditions":"Multiple Sclerosis","enrollment":200},{"nctId":"NCT00726700","phase":"PHASE2","title":"Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Universität des Saarlandes","startDate":"2004-05","conditions":"Lymphoma","enrollment":109},{"nctId":"NCT00052936","phase":"PHASE3","title":"Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"German High-Grade Non-Hodgkin's Lymphoma Study Group","startDate":"2001-01","conditions":"Lymphoma","enrollment":1506},{"nctId":"NCT02304354","phase":"PHASE3","title":"Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX)","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2015-03-09","conditions":"Rheumatoid Arthritis","enrollment":70},{"nctId":"NCT03979456","phase":"PHASE3","title":"RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS","status":"UNKNOWN","sponsor":"Karolinska Institutet","startDate":"2018-07-04","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":200},{"nctId":"NCT02128061","phase":"PHASE3","title":"Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2014-08","conditions":"Diffuse Large B Cell Lymphoma","enrollment":250},{"nctId":"NCT00278421","phase":"PHASE3","title":"Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"German High-Grade Non-Hodgkin's Lymphoma Study Group","startDate":"2005-11","conditions":"Lymphoma","enrollment":592},{"nctId":"NCT02165397","phase":"PHASE3","title":"Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2014-07-07","conditions":"Waldenström's Macroglobulinemia","enrollment":181},{"nctId":"NCT03002038","phase":"PHASE2, PHASE3","title":"Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients","status":"COMPLETED","sponsor":"Isfahan University of Medical Sciences","startDate":"2015-09","conditions":"Neuromyelitis Optica Spectrum Disorder","enrollment":86},{"nctId":"NCT02468791","phase":"PHASE3","title":"MabionCD20® Compared to MabThera® in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Mabion SA","startDate":"2013-05","conditions":"Rheumatoid Arthritis","enrollment":709},{"nctId":"NCT04274257","phase":"PHASE2, PHASE3","title":"A Study of the Efficacy and Safety of Rituximab in Participants With Systemic Sclerosis","status":"COMPLETED","sponsor":"Tokyo University","startDate":"2017-12-04","conditions":"Scleroderma, Systemic, Skin Sclerosis, Lung Fibrosis","enrollment":56},{"nctId":"NCT00691652","phase":"PHASE1, PHASE2","title":"Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2008-05","conditions":"Lymphoma","enrollment":2},{"nctId":"NCT03061838","phase":"PHASE1","title":"Safety, Tolerability, PK and PD of Biosimilar Drug Ritumax® Compared to Original Drug MabThera®","status":"TERMINATED","sponsor":"Biointegrator LLC","startDate":"2016-10-27","conditions":"Rheumatoid Arthritis","enrollment":8},{"nctId":"NCT02187861","phase":"PHASE2","title":"A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-12-01","conditions":"Follicular Lymphoma","enrollment":163},{"nctId":"NCT01180036","phase":"PHASE2, PHASE3","title":"MEmbranous Nephropathy Trial Of Rituximab","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2011-11","conditions":"Idiopathic Membranous Nephropathy","enrollment":130},{"nctId":"NCT00774202","phase":"PHASE2, PHASE3","title":"Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2003-11","conditions":"Immune Thrombocytopenic Purpura","enrollment":17},{"nctId":"NCT03298698","phase":"PHASE3","title":"Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2018-08-22","conditions":"Idiopathic Nephrotic Syndrome, Minimal Change Disease, Focal Segmental Glomerulosclerosis","enrollment":40},{"nctId":"NCT02251964","phase":"PHASE2, PHASE3","title":"Rituximab in Interstitial Pneumonitis","status":"COMPLETED","sponsor":"Human Adams","startDate":"2014-09","conditions":"Lung Diseases, Interstitial, Pneumonitis, Interstitial","enrollment":20},{"nctId":"NCT01266317","phase":"PHASE1, PHASE2","title":"Combined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations","status":"COMPLETED","sponsor":"Michael Donahoe","startDate":"2011-03","conditions":"IPF","enrollment":9},{"nctId":"NCT00068250","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2003-07","conditions":"Brain and Central Nervous System Tumors, Lymphoma","enrollment":60},{"nctId":"NCT02744196","phase":"PHASE3","title":"Clinical Trial to Evaluate Efficacy and Safety of Acellbia® (JSC \"BIOCAD\") With Methotrexate in First Line Biological Therapy of Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Biocad","startDate":"2015-01","conditions":"Rheumatoid Arthritis","enrollment":159},{"nctId":"NCT00299104","phase":"PHASE3","title":"A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2006-01","conditions":"Rheumatoid Arthritis","enrollment":755},{"nctId":"NCT00426543","phase":"PHASE2","title":"Effect of B-cell Depletion in Patients With Primary Sjögren's Syndrome","status":"COMPLETED","sponsor":"University of Copenhagen","startDate":"2007-01","conditions":"Primary Sjögren's Syndrome, Xerostomia, Hyposalivation","enrollment":21},{"nctId":"NCT00656656","phase":"PHASE2","title":"Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus","status":"COMPLETED","sponsor":"University of Luebeck","startDate":"2008-01","conditions":"Pemphigus","enrollment":23},{"nctId":"NCT00590447","phase":"PHASE2","title":"Risk Stratified Sequential Treatment for CD20-positive PTLD","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2006-12","conditions":"PTLD, Posttransplant Lymphoproliferative Disorder","enrollment":152},{"nctId":"NCT00201721","phase":"PHASE2","title":"Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2002-07","conditions":"B-Chronic Lymphocytic Leukemia","enrollment":28},{"nctId":"NCT02966717","phase":"PHASE2","title":"Rituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD)","status":"UNKNOWN","sponsor":"Zhujiang Hospital","startDate":"2016-08","conditions":"Renal Insufficiency, Chronic, Nephrotic Syndrome","enrollment":116},{"nctId":"NCT01279902","phase":"PHASE2","title":"Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2010-08","conditions":"Diffuse Large B-cell Lymphoma","enrollment":32},{"nctId":"NCT00908583","phase":"PHASE4","title":"Desensitization in Kidney Transplantation","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2009-05","conditions":"HLA Sensitization","enrollment":44},{"nctId":"NCT00280241","phase":"PHASE2","title":"Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2004-06","conditions":"Chronic Lymphocytic Leukemia","enrollment":65},{"nctId":"NCT00595335","phase":"PHASE2, PHASE3","title":"Trial of Rituximab for Graves' Ophthalmopathy","status":"COMPLETED","sponsor":"Rebecca Bahn","startDate":"2008-04","conditions":"Thyroid-associated Ophthalmopathy","enrollment":25},{"nctId":"NCT00324779","phase":"PHASE2","title":"Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"University Hospital Erlangen","startDate":"2004-03","conditions":"Leukemia, Lymphoma","enrollment":79},{"nctId":"NCT00578305","phase":"PHASE3","title":"A Study of Rituximab (MabThera®/Rituxan®) in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-11","conditions":"Rheumatoid Arthritis","enrollment":185},{"nctId":"NCT01268033","phase":"PHASE2, PHASE3","title":"Efficacy of Rituximab For the Treatment of Calcineurin Inhibitors Dependent Nephrotic Syndrome During Childhood","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2010-12","conditions":"Childhood Idiopathic Nephrotic Syndrome","enrollment":26},{"nctId":"NCT00525616","phase":"PHASE3","title":"Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2008-12","conditions":"Bullous Pemphigoid","enrollment":18},{"nctId":"NCT01073163","phase":"PHASE3","title":"Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)","status":"COMPLETED","sponsor":"Cephalon","startDate":"2010-02","conditions":"Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma","enrollment":54},{"nctId":"NCT00799773","phase":"PHASE3","title":"Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)","status":"TERMINATED","sponsor":"Carelon Research","startDate":"2009-04","conditions":"Thrombotic Thrombocytopenic Purpura","enrollment":3},{"nctId":"NCT00048737","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2002-10","conditions":"Lymphoma, Leukemia","enrollment":70},{"nctId":"NCT01032122","phase":"PHASE1","title":"Rituximab in Metastatic Melanoma","status":"TERMINATED","sponsor":"Medical University of Vienna","startDate":"2007-10","conditions":"Metastatic Melanoma","enrollment":9}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Rituximab window","genericName":"Rituximab window","companyName":"University Hospital Muenster","companyId":"university-hospital-muenster","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rituximab is a chimeric monoclonal antibody that depletes B cells by binding to CD20 antigen, reducing autoimmune and inflammatory responses. Used for Rheumatoid arthritis (phase 3 trial context).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}